DFTX (Definium Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

DFTX (Definium Therapeutics, Inc.) Stock Financials & Earnings | Market Cap Arena

DFTXDefinium Therapeutics, Inc.

Mkt Cap$2B

Healthcare·Medical - Pharmaceuticals·🇺🇸 United States·NASDAQ

Revenue (TTM)$0

Net Income (TTM)-$184M

EPS (TTM)-$2.13

Free Cash Flow (TTM)-$161M

Gross Margin—

Op. Margin—

Net Margin—

FCF Margin—

P/S Ratio (TTM)—

P/E Ratio (TTM)—

YoY Rev Growth—

Employees—

Earnings Reports

Revenue & Profitability

Quarter	Revenue	Gross Profit	Op. Income
Q1 23	$0	$0	-$21M
Q2 23	$0	$0	-$29M
Q3 23	$0	$0	-$22M
Q4 23	$0	$0	-$22M
Q1 24	$0	-$527K	-$22M
Q2 24	$0	$0	-$24M
Q3 24	$0	$0	-$25M
Q4 24	$0	$0	-$32M
Q1 25	$0	$0	-$32M
Q2 25	$0	$0	-$41M
Q3 25	$0	$0	-$46M
Q4 25	$0	$0	-$48M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 23	-$13M	-$13M
Q2 23	-$14M	-$14M
Q3 23	-$17M	-$17M
Q4 23	-$21M	-$21M
Q1 24	-$17M	-$17M
Q2 24	-$20M	-$20M
Q3 24	-$17M	-$17M
Q4 24	-$25M	-$25M
Q1 25	-$29M	-$29M
Q2 25	-$30M	-$30M
Q3 25	-$30M	-$30M
Q4 25	-$73M	-$73M

Capital Expenditures

CapEx

Quarter	CapEx
Q1 23	$0
Q2 23	$0
Q3 23	$0
Q4 23	$0
Q1 24	$0
Q2 24	$0
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$0
Q3 25	$0
Q4 25	$0

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 23	—	+12.7%
Q2 23	—	+72.2%
Q3 23	—	+27.3%
Q4 23	—	+59.7%
Q1 24	—	+6.4%
Q2 24	—	-16.2%
Q3 24	—	+14.7%
Q4 24	—	+46.2%
Q1 25	—	+44.8%
Q2 25	—	+67.2%
Q3 25	—	+84.2%
Q4 25	—	+46.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 23	$4M	—
Q2 23	$4M	—
Q3 23	$4M	—
Q4 23	$4M	—
Q1 24	$4M	—
Q2 24	$5M	—
Q3 24	$4M	—
Q4 24	$3M	—
Q1 25	$3M	—
Q2 25	$5M	—
Q3 25	$6M	—
Q4 25	$11M	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 23	$13M	$8M
Q2 23	$15M	$14M
Q3 23	$13M	$8M
Q4 23	$12M	$11M
Q1 24	$11M	$10M
Q2 24	$15M	$10M
Q3 24	$17M	$8M
Q4 24	$22M	$11M
Q1 25	$23M	$9M
Q2 25	$30M	$11M
Q3 25	$31M	$15M
Q4 25	$34M	$14M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 23	$129M	$0	$129M
Q2 23	$117M	$0	$117M
Q3 23	$118M	$0	$118M
Q4 23	$100M	$0	$100M
Q1 24	$252M	$0	$252M
Q2 24	$243M	$0	$243M
Q3 24	$295M	$0	$295M
Q4 24	$274M	$0	$274M
Q1 25	$83M	$130M	$212M
Q2 25	$33M	$150M	$183M
Q3 25	$20M	$189M	$209M
Q4 25	$258M	$154M	$412M

Shares Outstanding

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change
Q1 23	38M	+0.3%
Q2 23	39M	+1.3%
Q3 23	40M	+3.0%
Q4 23	40M	+1.4%
Q1 24	48M	+18.8%
Q2 24	72M	+50.3%
Q3 24	80M	+11.6%
Q4 24	84M	+4.6%
Q1 25	87M	+3.8%
Q2 25	85M	-2.0%
Q3 25	86M	+0.6%
Q4 25	89M	+4.0%

Revenue Per Employee

Revenue / Employee

Year	Revenue/Employee	Employees
FY 15	—	—
FY 16	—	—
FY 17	—	—
FY 18	—	—
FY 19	—	—
FY 20	—	—
FY 21	$0	41
FY 22	$0	48
FY 23	$0	57
FY 24	$0	74
FY 25	$0	105